Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
- PMID: 21453539
- PMCID: PMC3080296
- DOI: 10.1186/1471-2377-11-43
Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
Abstract
Background: Pain in general and headache in particular are characterized by a change in activity in brain areas involved in pain processing. The therapeutic challenge is to identify drugs with molecular targets that restore the healthy state, resulting in meaningful pain relief or even freedom from pain. Different aspects of pain perception, i.e. sensory and affective components, also explain why there is not just one single target structure for therapeutic approaches to pain. A network of brain areas ("pain matrix") are involved in pain perception and pain control. This diversification of the pain system explains why a wide range of molecularly different substances can be used in the treatment of different pain states and why in recent years more and more studies have described a superior efficacy of a precise multi-target combination therapy compared to therapy with monotherapeutics.
Discussion: In this article, we discuss the available literature on the effects of several fixed-dose combinations in the treatment of headaches and discuss the evidence in support of the role of combination therapy in the pharmacotherapy of pain, particularly of headaches. The scientific rationale behind multi-target combinations is the therapeutic benefit that could not be achieved by the individual constituents and that the single substances of the combinations act together additively or even multiplicatively and cooperate to achieve a completeness of the desired therapeutic effect.As an example the fixed-dose combination of acetylsalicylic acid (ASA), paracetamol (acetaminophen) and caffeine is reviewed in detail. The major advantage of using such a fixed combination is that the active ingredients act on different but distinct molecular targets and thus are able to act on more signalling cascades involved in pain than most single analgesics without adding more side effects to the therapy.
Summary: Multitarget therapeutics like combined analgesics broaden the array of therapeutic options, enable the completeness of the therapeutic effect, and allow doctors (and, in self-medication with OTC medications, the patients themselves) to customize treatment to the patient's specific needs. There is substantial clinical evidence that such a multi-component therapy is more effective than mono-component therapies.
Similar articles
-
OTC analgesics in headache treatment: open-label phase vs randomized double-blind phase of a large clinical trial.Headache. 2009 May;49(5):638-45. doi: 10.1111/j.1526-4610.2009.01402.x. Headache. 2009. PMID: 19472437 Clinical Trial.
-
The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study.Cephalalgia. 2011 Oct;31(14):1466-76. doi: 10.1177/0333102411419682. Epub 2011 Sep 9. Cephalalgia. 2011. PMID: 21908446 Clinical Trial.
-
Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension-type headache: meta-analysis of four randomized, double-blind, placebo-controlled, crossover studies.J Headache Pain. 2014 Nov 19;15(1):76. doi: 10.1186/1129-2377-15-76. J Headache Pain. 2014. PMID: 25406671 Free PMC article.
-
Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review.Eur J Neurol. 2010 Apr;17(4):534-e25. doi: 10.1111/j.1468-1331.2009.02922.x. Epub 2010 Jan 13. Eur J Neurol. 2010. PMID: 20074228 Review.
-
[Effectiveness of fixed analgesic combinations exemplified by thomapyrin].Wien Klin Wochenschr. 1996;108(8):219-33. Wien Klin Wochenschr. 1996. PMID: 8686313 Review. German.
Cited by
-
Italian guidelines for primary headaches: 2012 revised version.J Headache Pain. 2012 May;13 Suppl 2(Suppl 2):S31-70. doi: 10.1007/s10194-012-0437-6. J Headache Pain. 2012. PMID: 22581120 Free PMC article.
-
Design, synthesis, analgesic, antibacterial and docking studies of novel 8-piperazinylcaffeine carboxylate ionic liquids.RSC Adv. 2024 Sep 10;14(39):28669-28683. doi: 10.1039/d4ra06244b. eCollection 2024 Sep 4. RSC Adv. 2024. PMID: 39257660 Free PMC article.
-
Liquid Co-crystals of Dual-Active Phenothiazine-NSAID Drugs: Synthesis, Spectroscopic, and Thermal Characterization.ACS Omega. 2022 May 9;7(20):16990-17001. doi: 10.1021/acsomega.1c07382. eCollection 2022 May 24. ACS Omega. 2022. PMID: 35647432 Free PMC article.
-
Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study.Adv Ther. 2019 Mar;36(3):597-607. doi: 10.1007/s12325-019-0891-5. Epub 2019 Feb 13. Adv Ther. 2019. PMID: 30758744 Free PMC article. Clinical Trial.
-
Novel analgesic combination of tramadol, paracetamol, caffeine and taurine in the management of moderate to moderately severe acute low back pain.J Orthop. 2013 Jul 22;10(3):144-8. doi: 10.1016/j.jor.2013.07.001. eCollection 2013. J Orthop. 2013. PMID: 24396231 Free PMC article.
References
-
- Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444(7121):894–898. doi: 10.1038/nature05413. - DOI - PMC - PubMed
-
- Piguet V, Allaz AF. Complexite de la douleur: du savoir a la provocation [The complexity of pain and its origins - in French] Rev Medicale Suisse. 2005;1(25):1651–1652. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical